Havana, Cuba: The Cuban Biotechnological and Pharmaceutical Industries Group (BioCubaFarma) announced the day before that the dossier of its Abdala vaccine against COVID-19 is ready to be reviewed by experts from the World Health Organization (WHO), Tribuna de La Habana publishes.
Through its Twitter account, BioCubaFarma reported that “the Center for Genetic Engineering and Biotechnology (CIGB) began a formal exchange with the World Health Organization in March to start the process of evaluating its anti-virus vaccine. Covid19, Abdala”.
The BioCubaFarma business group highlighted that “the WHO has already been informed that the dossier is ready to be reviewed by experts.”
Also in another tweet, he specified that “the Finlay Vaccine Institute and the CIGB are working to soon present to the @cubacecmed (Medication, Equipment and Medical Devices Regulatory Authority of the Republic of Cuba) the data from the clinical studies of Soberana 01 and Mambisa. We continue to advance in the development strategy of the #VacunasCubanasCovid19”.
He also highlighted that “Cuban anti-Covid19 vaccines have shown a significant reduction in infections and deaths in the country.”
As of March 31, Cuba reports a cumulative rate of deaths per million inhabitants three times lower than those reported in Europe and the American continent, highlighted the Group of Biotechnological and Pharmaceutical Industries of the Caribbean nation.